Oppenheimer assumed coverage on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a report published on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $50.00 price target on the specialty pharmaceutical company’s stock. Other research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Collegium […]